Therapeutic compositions, combinations, and methods of use
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12280050-B2
Publication Date
2025-04-22
Expiration Date
Abstract
This invention relates to methods comprising administering a FAK inhibitor (e.g., VS-6063) in combination with a dual RAF/MEK inhibitor (e.g., CHS 126766) that are useful in the treatment of abnormal cell growth, such as cancer, in a subject such as humans.
Core Innovation
The invention relates to a method of treating pancreatic cancer in a subject in need thereof. The method comprises orally administering an effective amount of CH5126766, or a pharmaceutically acceptable salt thereof, in combination with an effective amount of defactinib, or a pharmaceutically acceptable salt thereof.
CH5126766, or a pharmaceutically acceptable salt thereof, and defactinib, or a pharmaceutically acceptable salt thereof, are administered as a cycle comprising administering CH5126766 twice a week and defactinib twice daily for three weeks. The cycle then includes not administering CH5126766 and not administering defactinib for one week, establishing a repeating on-and-off structure for both agents.
The patent also specifies additional features within dependent claims that further define the pancreatic cancer and subject selection, including mutation-related limitations. Certain embodiments require particular RAS mutation types and can restrict the method to pancreatic cancer that is metastatic, thereby narrowing the treated population and disease state while retaining the defined CH5126766 and defactinib cycling schedule.
Claims Coverage
The partial content identifies one independent claim directed to treating pancreatic cancer using an orally administered CH5126766/defactinib combination given in a specific cycling schedule. The main inventive features are the drug combination and the structured treatment cycle timing for CH5126766 and defactinib.
Oral CH5126766 and defactinib combination for pancreatic cancer
A method of treating pancreatic cancer in a subject in need thereof comprising orally administering an effective amount of CH5126766 (or a pharmaceutically acceptable salt thereof) in combination with an effective amount of defactinib (or a pharmaceutically acceptable salt thereof).
Defined CH5126766 and defactinib cycle with three weeks on and one week off
CH5126766 and defactinib are administered as a cycle comprising administering CH5126766 twice a week and defactinib twice daily for three weeks and then not administering CH5126766 and not administering defactinib for one week.
In the provided claim text, the independent claim’s coverage centers on orally treating pancreatic cancer with a CH5126766 plus defactinib combination while implementing a specific cycle where both drugs follow three weeks of dosing followed by a one-week pause with not administering either agent.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?